SGO 2019: Despite Missed Endpoint, JAVELIN Trial PD-L1 Subgroup Analysis Redeems


Avelumab alone or with pegylated liposomal doxorubicin did not improve survival in this phase III trial, but a subgroup analysis showed promising findings.

Avelumab alone or in combination with pegylated liposomal doxorubicin did not improve survival for patients with platinum-resistant or refractory epithelial ovarian cancer compared with patients who received pegylated liposomal doxorubicin alone, according to results from the randomized, open-label, phase III JAVELIN Ovarian 200 trial presented at the 2019 Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women’s Cancer (LBA1).

Despite the negative trial findings, however, a retrospective subgroup analysis showed that patients with programmed death ligand 1 (PD-L1)-positive disease may benefit from the combination of avelumab plus pegylated liposomal doxorubicin.

“This is a very interesting study looking at the role of the immunotherapeutic avelumab, a PD-L1 antibody, in recurrent platinum-resistant ovarian cancer,” Heidi Gray, MD, an associate professor in the Division of Gynecologic Oncology at University of Washington/Seattle Cancer Care Alliance, told Cancer Network during an interview.

The trial ( identifier: NCT02580058) included 566 women with platinum-resistant or refractory ovarian cancer. Trial eligibility included three or fewer lines of therapy for patients with platinum-sensitive disease; patients with platinum-resistant disease were not permitted to have any prior lines of therapy.

Patients were randomized in a 1:1:1 fashion to one of three treatment arms: avelumab alone, avelumab plus pegylated liposomal doxorubicin, or pegylated liposomal doxorubicin alone. Progression-free survival (PFS) and overall survival (OS) were the primary endpoints. One of the secondary endpoints was a retrospective analysis of patients grouped by PD-L1 status (positive vs negative).

Compared with the pegylated liposomal doxorubicin arm, the avelumab alone arm had neither improved median PFS (3.5 vs 1.9 months; hazard ratio [HR], 1.68; P > .999) nor median OS (13.1 vs 11.8 months; HR, 1.14; P = .8253). Compared with the pegylated liposomal doxorubicin arm, the avelumab plus pegylated liposomal doxorubicin arm failed to significantly improve median PFS (3.5 vs 3.7 months; HR, 0.78; P = 0.0301) and median OS (13.1 vs 15.7 months; HR, 0.89; P = .2082).

The overall response rate (ORR) was 4.2% (95% CI, 1.8–8.1) for the pegylated liposomal doxorubicin alone arm compared with 3.7% (95% CI, 1.5–7.5) for the avelumab alone arm and 13.3% (95% CI, 8.8–19.0) for the avelumab plus pegylated liposomal doxorubicin arm. About the ORRs, Gray said, “In general, these are low response rates, as a large percentage of patients were enrolled with poor prognosis.” She noted that a quarter of patients were primary platinum refractory, and close to 50% had primary platinum resistance (ie, only one line of prior therapy).

The retrospective PD-L1 subgroup analysis, for which 442 patients were evaluable, revealed that patients with PD-L1–positive disease may benefit from avelumab plus pegylated liposomal doxorubicin. For the avelumab plus pegylated liposomal doxorubicin arm, patients with PD-L1–positive tumors had a higher ORR than those with PD-L1–negative tumors (18.5% vs 3.4%). These PD-L1 positive patients who received the avelumab combination therapy had similar PFS (3.7 vs 3.9 months) and improved OS (18.4 vs 12.7 months) compared with PD-L1–negative patients.

“In the subgroup analysis, patients with PD-L1–positive tumors had a trend to higher ORR,” said Gray. “I think this leaves room for future clinical trials with avelumab in combination with chemotherapy, especially in PD-L1–positive tumors.” 

Related Videos
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Related Content